COVID-19 Science Spotlight

Here’s why I believe that antivirals should be administered to all adults aged 65 and older with early COVID-19 to reduce their risks of severe disease, hospitalization, and death.

Josep M. Llibre, MD, PhD Released: September 22, 2022

Long COVID is a difficult syndrome to define and study and it has no current treatment options. Read my take on what we think causes long COVID and why avoiding COVID-19 infections is key to preventing this syndrome. 

David A. Wohl, MD Released: October 10, 2022

Patients with COVID-19 and renal dysfunction require special considerations when prescribing antiviral treatment. Read my take on how to assess risk vs benefit of COVID-19 antiviral use in these patients.

Lynora Saxinger, MD, FRCPC, CTropMed Released: October 21, 2022

Read my take on why receiving a COVID-19 bivalent booster is of utmost importance for staying protected against this constantly evolving virus.

Tracey Piparo, PA-C Released: November 3, 2022

Patients with immunocompromise are at risk for poor outcomes if infected with COVID-19. Read my take on why COVID-19 prevention in this population is so important.

Alicia Lichvar, PharmD, MS, BCPS, BCTXP Released: November 17, 2022

COVID-19 antiviral agents have shown benefit in reducing not only hospitalization and mortality risk, but also symptom duration and viral load. Are we going to see a shift toward antiviral use in low-risk patients with COVID-19 for the purpose of symptom alleviation?

Roger Paredes, MD, PhD Released: December 6, 2022

Monoclonal antibodies were previously a cornerstone of therapy for early COVID-19, but emerging omicron subvariants have compromised their in vitro activity. What does this mean for our COVID-19 treatment paradigm?

Arthur Kim, MD Released: December 19, 2022

Expert discussion of landmark clinical trials of COVID-19 antivirals for nonhospitalized patients and the COVID-19 rebound phenomenon.

Jason Gallagher, PharmD Emily Heil, PharmD, MS, BCIDP, AAHIVP Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: November 22, 2022 Expired: No longer available for credit

Expert discussion of long COVID definitions, diagnosis, epidemiology, risk factors, treatment options, and clinical guidance statements.

Alba Azola, MD Monica Verduzco-Gutierrez, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: January 10, 2023 Expired: No longer available for credit